LISTING OF THE CLAIMS

The following listing of the claims replaces all prior claims in the application:

1. (Currently Amended) A method for inducing T-cell tolerance or non- responsiveness of donor T-cells to desired alloantigen-bearing cells *ex vivo* comprising the following:

(i) ~~providing a culture containing donor tissue containing donor T-cells~~ purifying $CD4^+$ T-cells from donor tissue;

(ii) irradiating alloantigen-bearing cells obtained from a recipient to deplete recipient T-cells;

~~(ii)~~ (iii) producing a mixed lymphocyte reaction culture ~~by adding to said donor T-cell culture~~ comprising the purified donor $CD4^+$ T-cells and irradiated, T-cell depleted alloantigen-bearing cells obtained from a recipient;

~~(iii)~~ (iv) adding an anti-gp39 antibody to the ~~mixed lymphocyte reaction~~ culture, thereby initiating a mixed lymphocyte reaction culture comprising purified donor $CD4^+$ T-cells, T-cell depleted recipient alloantigen-bearing cells, and anti-gp39 antibody;

~~(iv)~~ (v) maintaining the mixed lymphocyte reaction culture *ex vivo* for a sufficient time to render the donor $CD4^+$ T-cells substantially tolerant or non-responsive to said alloantigen-bearing cells, and

~~(v)~~ (vi) assaying *ex vivo* for induction of donor $CD4^+$ T-cell tolerance or non-responsiveness.

2. (Currently Amended) The method of Claim 1, wherein the donor tissue ~~containing donor T-cells~~ is donor bone marrow or peripheral blood cells.

3. (Canceled)

4. (Previously Presented) The method of Claim 1, wherein the gp39 antibody is an anti-human gp39 monoclonal antibody.

5. (Previously Presented) The method of Claim 4, wherein said anti-gp39 antibody is a chimeric or humanized anti-human gp39 monoclonal antibody.

6. (Currently Amended) The method of Claim 1, wherein the donor T-cells are cultured in step (iv) for a time ranging from about ~~1~~ 5 to 30 days.

7. (Currently Amended) The method of Claim 6, wherein said ~~time ranges from about 5 to 15~~ donor T-cells are cultured in step (v) for a time ranging from 6 to 10 days.

8. (Canceled) The method of Claim 1, wherein the alloantigen-bearing cells have been treated to deplete recipient T-cells.

9. (Canceled) The method of Claim 8, wherein recipient T-cell depletion is effected by irradiation.

10. (Previously Presented) The method of Claim 1, wherein the donor T-cells that have been determined to be tolerized by the assay of step (vi) are transplanted into a recipient in need of such transplantation.

11. (Original) The method of Claim 10, wherein the recipient is in need of immune reconstitution as a result of disease or disease treatment.

12. (Canceled)

13. (Previously Presented) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring IL-2 concentration in the cell culture medium supernatants of the donor T-cells cultured in step (v) and of control donor T-cells, wherein detection of reduced IL-2 concentration in the supernatant of the donor T-cells cultured in step (v), relative to the IL-2 concentration in the supernatant of control T-cells, is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

14. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring the concentration of interferon-gamma in the cell culture medium supernatants of the donor T-cells cultured in step (v) and of control donor T-cells,

wherein detection of reduced interferon-gamma concentration in the supernatant of the donor T-cells cultured in step (v) relative to that of the control T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

15. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises assaying to detect at least one antigen selected from the group consisting of L-selectin, ICAM-1, and CD45 in the donor T-cells cultured in step iv and control donor T-cells,

wherein detection of an increased amount of L-selectin or ICAM-1, or a reduced amount of CD45 in the donor T-cells cultured in step (v) relative to that in the control donor T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.